JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

CD40 Ligand Blockade for Prevention of Graft-Versus-Host Disease This scoping review was conducted based on the Arksey and O'Malley framework and the work of Levac et al. The databases searched ...

This study evaluated three LLMs (GPT-3.5-turbo-0125, GPT-4-turbo, and GPT-4o) using drug names from HemOnc ontology. The assessment included 367 generic-to-brand and 2,516 brand-to-generic pairs, ...

Research suggests that a substantial proportion of those diagnosed with cancer may experience portions of their diagnosis and treatment as traumatic. 6 Additionally, many individuals diagnosed with ...

Tumor-treating fields (TTFs) use alternating electric fields to disrupt cancer cell proliferation in preclinical models. 8 More importantly, TTFs have been clinically validated, leading to an improved ...

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three ...

Frustrations regarding the costs and difficulties with parking at hospitals is a common concern voiced by patients, families, and healthcare providers. Transportation barriers to receiving cancer care ...

Deep Learning Model for Natural Language to Assess Effectiveness of Patients With Non–Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus Calmette-Guérin Therapy Accurate identification of ...

The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy ...

The article by Arnold et al titled “Outcomes of Adolescent and Young Adult Women With Breast Cancer in Rural and Urban Saskatchewan: A Retrospective Cohort Study” (J Glob Oncol 10.1200/GO-25-00018) ...

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate ...

Colorectal cancer (CRC) is the third most common cancer worldwide, responsible for approximately 10% of all cancer cases and is the second leading cause of cancer-related deaths according to WHO. 1 ...